Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Amber C Streifel; Luke C Strnad; Monica K Sikka; Cara D Varley; Jina Makadia; Ellie Sukerman; Alyse H Douglass; Heather Mayer; Kathleen Young; James S Lewis 2nd

doi:10.1093/ofid/ofae070

Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Open Forum Infect Dis. 2024 Feb 7;11(3):ofae070. doi: 10.1093/ofid/ofae070. eCollection 2024 Mar.

Authors

Affiliations

¹ Department of Pharmacy, Oregon Health & Science University, Portland, Oregon, USA.
² Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.
³ School of Public Health, Epidemiology Programs, Oregon Health & Science University and Portland State University, Portland, Oregon, USA.

Abstract

Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

Keywords: OPAT; long-acting glycopeptides; vertebral osteomyelitis.

Publication types

Clinical Trial